<DOC>
	<DOCNO>NCT01370551</DOCNO>
	<brief_summary>The purpose study assess longterm safety efficacy vaginal application Gynoflor® , extremely low dose estrogen therapy lactobacillus , atrophic vaginitis postmenopausal breast cancer patient treat aromatase inhibitor .</brief_summary>
	<brief_title>Clinical Study Vaginal Lactobacilli Estriol ( Gynoflor® ) Atrophic Vaginitis Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Vaginitis</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Atrophic Vaginitis</mesh_term>
	<criteria>1 . Patients breast cancer nonsteroidal AI therapy ( AI therapy start least 6 month ago , schedule receive study ) 2 . Postmenopausal age ≥52 cessation menses least 12 month 3 . Age 52 75 year 4 . Clinical symptom vaginal atrophy 5 . Vaginal pH &gt; 5.0 6 . Karnofsky score ≥80 % 7 . Signed Informed Consent Form together contractual capability 1 . Local systemic use sexual hormone ( estrogen , progestin , androgen ) , 6 month study 2 . Local systemic use phytoestrogens product know take improve vaginal mucosal function , risk vaginal infection , vulvovaginal symptom , 4 week study 3 . Local systemic use antiinfectives , 2 week study 4 . Use vaginal medication , vaginal rinse and/or moisturizers , gel contain xylocain analgesic product decrease pain intercourse , 1 week study 5 . Known suspected hypersensitivity intolerance study medication , inclusive excipients 6 . Suspicion clinically manifest STDs ( infection Neisseria gonorrhoea , Chlamydia trachomatis , Treponema pallidum , genital herpes , Trichomonas vaginalis , genital condylomata , HIV ) 7 . Clinical evidence vaginal infection require extra treatment 8 . Any infection upper genital tract 9 . Hysterectomy 10 . Genital haemorrhage unknown origin 11 . Malignant precancerous condition uterus , vulva and/or vagina ( PAP smear less 3 year ago ) 12 . Acute thrombophlebitis , thromboembolic disorder history disorder association previous use oestrogen preparation 13 . Abuse alcohol drug 14 . All chronic illness could influence absorption , distribution , biotransformation elimination test preparation 15 . Patient condition situation , investigator ` opinion , may put patient significant risk , may confound study result , may interfere significantly patient ` participation study 16 . BMI low 18.5 high 30 17 . Patient steroidal AIs ( aromasin ) 18 . Vulvodermatological condition ( like Lichen sclerosus , Lichen rubrus , Psoriasis ) 19 . Genital prolapse 20 . Endometriosis 21 . Use antibiotics chemotherapeuticals harmful lactobacilli 22 . Participation patient another investigational drug study , exception treatment optimisation study nonsteroidal AIs 23 . Previous participation study 24 . Patient relative , staff directly report investigator 25 . Patient employee sponsor</criteria>
	<gender>Female</gender>
	<minimum_age>52 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>